NDAINJECTIONINJECTABLE
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bretylium tosylate is an injectable antiarrhythmic agent approved in 1986 for the treatment of life-threatening ventricular arrhythmias. It is administered intravenously and works through sympathomimetic and direct electrophysiologic effects on cardiac tissue. The drug is primarily used in acute care settings for patients with hemodynamically unstable arrhythmias.
LOE Approaching
This product is approaching loss of exclusivity with minimal linked job opportunities, indicating a shrinking commercial footprint and reduced team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job opportunities and approaching loss of exclusivity, this product offers minimal career growth potential and limited advancement prospects. Professionals assigned to this brand should expect a consolidating team focused on maximizing remaining exclusivity and preparing for generic transition.
Brand ManagerField Sales Representative
Worked on BRETYLIUM TOSYLATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.